Welcome to The Visible Embryo
The Visible Embryo Birth Spiral Navigation
Fetal Timeline--- -Maternal Timeline-----News-----Prescription Drugs in Pregnancy---- Pregnancy Calculator----Female Reproductive System

WHO International Clinical Trials Registry Platform

The World Health Organization (WHO) has a Web site to help researchers, doctors and patients obtain information on clinical trials.

Now you can search all such registers to identify clinical trial research around the world!




Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System


Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.

Content protected under a Creative Commons License.
No dirivative works may be made or used for commercial purposes.


Pregnancy Timeline by SemestersDevelopmental TimelineFertilizationFirst TrimesterSecond TrimesterThird TrimesterFirst Thin Layer of Skin AppearsEnd of Embryonic PeriodEnd of Embryonic PeriodFemale Reproductive SystemBeginning Cerebral HemispheresA Four Chambered HeartFirst Detectable Brain WavesThe Appearance of SomitesBasic Brain Structure in PlaceHeartbeat can be detectedHeartbeat can be detectedFinger and toe prints appearFinger and toe prints appearFetal sexual organs visibleBrown fat surrounds lymphatic systemBone marrow starts making blood cellsBone marrow starts making blood cellsInner Ear Bones HardenSensory brain waves begin to activateSensory brain waves begin to activateFetal liver is producing blood cellsBrain convolutions beginBrain convolutions beginImmune system beginningWhite fat begins to be madeHead may position into pelvisWhite fat begins to be madePeriod of rapid brain growthFull TermHead may position into pelvisImmune system beginningLungs begin to produce surfactant
CLICK ON weeks 0 - 40 and follow along every 2 weeks of fetal development

Developmental biology - Gene Function

Some children predisposed to develop leukemia

St. Jude's Research discovers a fourth gene that predisposes a carrier to the most common childhood cancer...

Some children are predisposed to develop leukemia, according to St. Jude Children's Research Hospital scientists who have discovered a gene that can predispose carriers to this most common of childhood cancers. Their discovery expands the list of genes for possible increased susceptibility to childhood leukemia. They report their findings online in the journal Cancer Cell.

The gene is IKZF1, which encodes the transcription factor IKAROS that regulates gene expression. IKZF1 is the fourth gene identified that - like the genes TP53, ETV6 and PAX5 - can predispose carriers to develop B-cell acute lymphoblastic leukemia (ALL). Variants in IKZF1 can also influence how some patients respond to treatment.

Researchers found a rare IKZF1 germline variant in three generations of a German family affected by pediatric ALL. St. Jude researchers then analyzed data from almost 5,000 young ALL patients and found that 0.9 percent of patients with B-cell ALL, the most common pediatric ALL, also carried germline variations in IKZF1. Germline variants are usually inherited in DNA.
"This finding adds to the growing body of evidence that, while germline variations still account for a small percentage of pediatric ALL cases overall, more children than previously recognized inherit a predisposition to develop ALL,"

Charles Mullighan MBBS MD, St. Jude Department of Pathology.

Jun J. Yang, Ph.D., an associate member of the St. Jude Department of Pharmaceutical Sciences and Department of Oncology, adds: "The results also show that germline variants influence the response of leukemia cells to specific chemotherapeutic agents." Mullighan and Yang are the study's corresponding authors.

"This will expand the number of genes to consider when screening for predisposition to leukemia, particularly B-ALL. And while not everyone carrying a germline IKZF1 variant will develop leukemia, these results will help us educate families about the potential risk of leukemia," adds co-author Kim Nichols, M.D., director of the St. Jude Cancer Predisposition Division. As a group, Mullighan, Yang and Nichols have led research that identified the four known pediatric ALL predisposition genes.
IKZF1 frequently mutated in leukemic cells.

The discovery comes a decade after Mullighan and his colleagues reported that IKZF1 was frequently mutated in leukemic cells and a harbinger of poor treatment outcomes.

The search for germline IKZF1 variants associated with ALL susceptibility began in Singapore. Nichols and Yang were there to talk about germline genetics of ALL and inherited (familial) cancer. During that visit, co-author Rupert Handgretinger, M.D., of Children's University Hospital, Tuebingen, Germany, mentioned three generations of a German family with a germline variation in IKZF1 and a family history of B-ALL. Two of the five family members with the variant had developed pediatric ALL and died. The remaining three are apparently healthy despite having reduced numbers of B cells.

Targeted sequencing of IKZF1 in 4,963 children with ALL identified 43 patients with 27 IKZF1 variants, almost exclusively patients with B-ALL. "The pattern of IKZF1 variants was surprising because many of the variants were in regions of the gene that are rarely mutated in leukemic cells; these regions of the gene have not been well characterized," Yang said.
IKZF1 variants affect IKAROS function.

Extensive laboratory testing found at least 22 of the 28 variants affected protein functions. For example, IKZF1 variants resulted in IKAROS migrating outside the nucleus, which is where the protein normally functions. In other cases, variants were associated with increased cell adhesion.

"Based on existing models, we would have predicted only 60 percent of the newly identified IKZF1 variants would be deleterious," says Michelle Churchman PhD, of St. Jude Pathology. Churchman and Maoxiang Qian PhD, of St. Jude Pharmaceutical Sciences, and Geertruy te Kronnie, of the University of Padova, Italy, are first authors of the paper.
But, a second variant "hit" causes cancer.

"In IKZF1 and the other ALL predisposition genes, cells may require an additional cooperating mutation to develop into leukemia," Mullighan adds. "While familial ALL is rare, these cases can point to genes and novel biology to examine in a larger patient population. This study demonstrates the power of sequencing large groups of seemingly sporadic cases that reveal the genetic underpinnings of the disease."

Germline coding IKZF1 variants are present in familial and sporadic B-precursor ALL
Most variants affect regions outside of known domains and perturb IKAROS function
Germline IKZF1 variants result in aberrant adhesion and bone marrow mislocalization
Germline IKZF1 variants result in reduced antileukemic drug sensitivity

Somatic genetic alterations of IKZF1, which encodes the lymphoid transcription factor IKAROS, are common in high-risk B-progenitor acute lymphoblastic leukemia (ALL) and are associated with poor prognosis. Such alterations result in the acquisition of stem cell-like features, overexpression of adhesion molecules causing aberrant cell-cell and cell-stroma interaction, and decreased sensitivity to tyrosine kinase inhibitors. Here we report coding germline IKZF1 variation in familial childhood ALL and 0.9% of presumed sporadic B-ALL, identifying 28 unique variants in 45 children. The majority of variants adversely affected IKZF1 function and drug responsiveness of leukemic cells. These results identify IKZF1 as a leukemia predisposition gene, and emphasize the importance of germline genetic variation in the development of both familial and sporadic ALL.

The study's other authors include Wenjian Yang, Paige Tedrick, Rebekah Baskin, Katherine Verbist, Jennifer Peters, Ian Moore, Zhaohui Gu, Chunxu Qu, Hiroki Yoshihara, Shaina Porter, Shondra Pruett-Miller, Gang Wu, William Evans, Mary Relling and Ching-Hon Pui, all of St. Jude; Hui Zhang of St. Jude and Guangzhou Women and Children's Medical Center, China; and researchers at 12 institutions in the U.S., China and Germany. The patients in this analysis were enrolled in clinical research conducted by St. Jude and the Children's Oncology Group, a cooperative clinical research network.

The study was funded in part by the St. Baldrick's Foundation, grants (GM115279, CA021765, CA176063, CA19769501A1, CA98543, CA114766, CA98413, CA180886, CA180899) from the National Institutes of Health; and ALSAC, the fundraising and awareness organization of St. Jude.

Return to top of page

Apr 26, 2018   Fetal Timeline   Maternal Timeline   News   News Archive

Genetic alterations of IKZF1 gene, which encodes the lymphoid factor IKAROS, are common in high-risk acute lymphoblastic leukemia (ALL) associated with a poor prognosis for the child. Image credit: Charles G. Mullighan MD, Department of Pathology, St. Jude Children's Research Hospital.

Phospholid by Wikipedia